A new biotech company forged through an Australian and Danish partnership will accelerate treatments for children and adults with heart disease. Harnessing cellular therapies, the company aims to conduct human clinical trials within three to five years.
Ibnova Therapeutics, launched today, has emerged from world-first, collaborative research by Murdoch Children’s Research Institute (MCRI) in Melbourne and QIMR Berghofer in Brisbane. Within MCRI, this work is supported by the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), which is headquartered in Copenhagen, and has research nodes in the University of Copenhagen, Leiden University Medical Center in the Netherlands and MCRI.
Based in Denmark, Ibnova Therapeutics is backed by the BioInnovation Institute (BII) Venture Lab program and…